Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis

Clinical Epigenetics

Brief Report

Cordula Engel¹  Steffen Koschmieder²  Edgar Jost²  Ledio Bocova³  Wouter Hubens³  Wolfgang Wagner⁴ 

[1] Department of Gynecology and Obstetrics, University Hospital of RWTH Aachen, Aachen, Germany;Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital of RWTH Aachen, Aachen, Germany;Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany;Institute for Stem Cell Biology, University Hospital of RWTH Aachen, Aachen, Germany;Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany;Institute for Stem Cell Biology, University Hospital of RWTH Aachen, Aachen, Germany;Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany;Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany;

关键词: DNA methylation;    Biomarker;    Epigenetic;    Hematopoietic stem cells;    HSC;    CD34;    Blast;    Leukemia;   

DOI  :  10.1186/s13148-023-01521-w

 received in 2023-02-23, accepted in 2023-06-15,  发布年份 2023

来源: Springer

【 摘 要 】

Hematopoietic stem and progenitor cells (HSPCs) are quantified in daily clinical practice by flow cytometry. In this study, we provide proof of concept that HSPCs can also be estimated by targeted DNA methylation (DNAm) analysis. The DNAm levels at three individual CG dinucleotides (CpG sites) in the genes MYO1D, STK17A, and SP140 correlated with CD34+ cell numbers in mobilized peripheral blood and with blast counts in leukemia. In the future, such epigenetic biomarkers can support the evaluation of stem cell mobilization, HSPC harvesting, or blast count in leukemia.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2023_37_Article_IEq130.gif

41116_2023_37_Article_IEq112.gif

Fig. 4

41116_2023_37_Article_IEq100.gif

41116_2023_37_Article_IEq91.gif

Fig. 4